If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ™ (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is tirzepatide indicated for patients with type 1 diabetes?
Tirzepatide is not indicated and has not been studied in people with type 1 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Type 1 Diabetes
Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of
- 30 kg/m2 or greater (obesity) or
- 27 kg/m2 or greater (overweight) with at least 1 weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes [T2D], obstructive sleep apnea, or cardiovascular disease).
Tirzepatide is not indicated in people with type 1 diabetes (T1D).
There is no information on the use of tirzepatide in people with T1D because patients with T1D were excluded from tirzepatide clinical trials.
Enclosed Prescribing Information
Date of Last Review: March 02, 2023